Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Cancer chemotherapy and pharmacology

Results: 1-25/180

Authors: STEWART DJ CRIPPS MC GOEL R DAHROUGE S YAU J TOMIAK E HUAN S SOLTYS K PROSSER A DAVIES RA
Citation: Dj. Stewart et al., PILOT-STUDY OF MULTIPLE CHEMOTHERAPY RESISTANCE MODULATORS PLUS EPIRUBICIN IN THE TREATMENT OF RESISTANT MALIGNANCIES, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 1-8

Authors: EGORIN MJ ROSEN DM BENJAMIN SE CALLERY PS SENTZ DL EISEMAN JL
Citation: Mj. Egorin et al., IN-VITRO METABOLISM BY MOUSE AND HUMAN LIVER PREPARATIONS OF HALOMON,AN ANTITUMOR HALOGENATED MONOTERPENE, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 9-14

Authors: SUONIO E LIPPONEN P MAENPAA J SYRJANEN K KANGAS L TUOMISTO L
Citation: E. Suonio et al., MITOTIC INDEX IN THE SUBRENAL CAPSULE ASSAY AS AN INDICATOR OF THE CHEMOSENSITIVITY OF OVARIAN-CANCER, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 15-21

Authors: POWIS G GALLEGOS A ABRAHAM RT ASHENDEL CL ZALKOW LH DORR R DVORAKOVA K SALMON S HARRISON S WORZALLA J
Citation: G. Powis et al., INHIBITION OF INTRACELLULAR CA2-ACTIVITY OF THE HERBICIDE ORYZALIN AND ITS ANALOGS( SIGNALING, CYTOTOXICITY AND ANTITUMOR), Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 22-28

Authors: AHMED AE JACOB S GIOVANELLA BC KOZIELSKI AJ LIEHR JG STEHLIN JS
Citation: Ae. Ahmed et al., COMPARATIVE DISPOSITION OF THE ANTINEOPLASTIC AGENT 9-NITIROCAMPTOTHECIN AND THE INACTIVE ISOMER 12-NITRO CAMPTOTHECIN IN CASE-BEARING NUDE-MICE - EFFECT OF ROUTE OF ADMINISTRATION ON TISSUE DISTRIBUTION, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 29-36

Authors: LOPES NM MILLER HP YOUNG ND BHUYAN BK
Citation: Nm. Lopes et al., ASSESSMENT OF MICROTUBULE STABILIZERS BY SEMIAUTOMATED IN-VITRO MICROTUBULE PROTEIN POLYMERIZATION AND MITOTIC BLOCK ASSAYS, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 37-47

Authors: SCHELLENS JHM VANDEVRIE W LOOS WJ KOLKER HJ VERWEIJ J STOTER G DURANTE NMC EGGERMONT AMM
Citation: Jhm. Schellens et al., PHARMACOKINETICS OF THE MULTIDRUG-RESISTANCE-CONVERTING DRUG DEXNIGULDIPINE AND ITS PYRIDINE METABOLITE M-1 IN THE PLASMA, TUMOR, AND RENALTISSUE OF TUMOR-BEARING WAG RIJ RATS/, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 48-52

Authors: GOSS PE FINE S GELMON K RUDINSKAS L OTTAWAY J MYLES J JAMES K PAUL K RODGERS A PRITCHARD KI
Citation: Pe. Goss et al., PHASE-I STUDIES OF FLUOROURACIL, DOXORUBICIN AND VINORELBINE WITHOUT (FAN) AND WITH (SUPERFAN) FOLINIC ACID IN PATIENTS WITH ADVANCED BREAST-CANCER, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 53-60

Authors: WOO ES MONKS A WATKINS SC WANG AS LAZO JS
Citation: Es. Woo et al., DIVERSITY OF METALLOTHIONEIN CONTENT AND SUBCELLULAR-LOCALIZATION IN THE NATIONAL-CANCER-INSTITUTE TUMOR PANEL, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 61-68

Authors: AU JLS KALNS J GAN YB WIENTJES MG
Citation: Jls. Au et al., PHARMACOLOGICAL EFFECTS OF PACLITAXEL IN HUMAN BLADDER-TUMORS, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 69-74

Authors: GANDARA DR EDELMAN MJ CROWLEY JJ LAU DHM LIVINGSTON RB
Citation: Dr. Gandara et al., PHASE-II TRIAL OF EDATREXATE PLUS CARBOPLATIN IN METASTATIC NON-SMALL-CELL LUNG-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 75-78

Authors: AMAR S GLOZMAN A CHUNG D ADLER V RONAI Z FRIEDMAN FK ROBINSON R BRANDTRAUF P YAMAIZUMI Z PINCUS MR
Citation: S. Amar et al., SELECTIVE-INHIBITION OF ONCOGENIC RAS-P21 IN-VIVO BY AGENTS THAT BLOCK ITS INTERACTION WITH JUN-N-KINASE (JNK) AND JUN PROTEINS - IMPLICATIONS FOR THE DESIGN OF SELECTIVE CHEMOTHERAPEUTIC-AGENTS, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 79-85

Authors: IAFFAIOLI RV FACCHINI G TORTORIELLO A CAPONIGRO F ILLIANO A GENTILE M GRAVINA A MUTO P
Citation: Rv. Iaffaioli et al., PHASE-I STUDY OF VINORELBINE AND PACLITAXEL IN SMALL-CELL LUNG-CANCER, Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 86-90

Authors: DUFFULL SB BEGG EJ ROBINSON BA DEELY JJ
Citation: Sb. Duffull et al., A SEQUENTIAL BAYESIAN ALGORITHM FOR DOSE INDIVIDUALIZATION OF CARBOPLATIN (VOL 39, PG 317, 1997), Cancer chemotherapy and pharmacology, 41(1), 1997, pp. 91-91

Authors: SAITO H OGAWA M OHNO R
Citation: H. Saito et al., THE 12TH BRISTOL-MYERS SQUIBB NAGOYA INTERNATIONAL CANCER-TREATMENT SYMPOSIUM - NEW THERAPEUTIC STRATEGIES FOR HIGHER CURE RATES - HIGH-DOSE THERAPY AND NEW THERAPEUTIC MODALITIES - PREFACE, Cancer chemotherapy and pharmacology, 40, 1997, pp. 1-2

Authors: LING V
Citation: V. Ling, MULTIDRUG-RESISTANCE - MOLECULAR MECHANISMS AND CLINICAL RELEVANCE, Cancer chemotherapy and pharmacology, 40, 1997, pp. 3-8

Authors: ESTEY E THALL P DAVID C
Citation: E. Estey et al., DESIGN AND ANALYSIS OF TRIALS OF SALVAGE THERAPY IN ACUTE MYELOGENOUSLEUKEMIA, Cancer chemotherapy and pharmacology, 40, 1997, pp. 9-12

Authors: SIKIC BI FISHER GA LUM BL HALSEY J BEKETICORESKOVIC L CHEN G
Citation: Bi. Sikic et al., MODULATION AND PREVENTION OF MULTIDRUG-RESISTANCE BY INHIBITORS OF P-GLYCOPROTEIN, Cancer chemotherapy and pharmacology, 40, 1997, pp. 13-19

Authors: NAITO M TSURUO T
Citation: M. Naito et T. Tsuruo, NEW MULTIDRUG-RESISTANCE-REVERSING DRUGS, MS-209 AND SDZ-PSC-833, Cancer chemotherapy and pharmacology, 40, 1997, pp. 20-24

Authors: SOIGNET S FLEISCHAUER A POLYAK T HELLER G WARRELL RP
Citation: S. Soignet et al., ALL-TRANS-RETINOIC ACID SIGNIFICANTLY INCREASES 5-YEAR SURVIVAL IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA - LONG-TERM FOLLOW-UP OF THE NEW-YORK STUDY, Cancer chemotherapy and pharmacology, 40, 1997, pp. 25-29

Authors: ASOU N ADACHI K TAMURA J KANAMARU A KAGEYAMA S HIRAOKA A OMOTO E SAKAMAKI H TSUBAKI K SAITO K OHNO R
Citation: N. Asou et al., ALL-TRANS-RETINOIC ACID THERAPY FOR NEWLY-DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA - COMPARISON WITH INTENSIVE CHEMOTHERAPY, Cancer chemotherapy and pharmacology, 40, 1997, pp. 30-35

Authors: KITAMURA K KIYOI H YOSHIDA H TOBITA T TAKESHITA A OHNO R NAOE T
Citation: K. Kitamura et al., NEW RETINOIDS AND ARSENIC COMPOUNDS FOR THE TREATMENT OF REFRACTORY ACUTE PROMYELOCYTIC LEUKEMIA - CLINICAL AND BASIC STUDIES FOR THE NEXT-GENERATION, Cancer chemotherapy and pharmacology, 40, 1997, pp. 36-41

Authors: FISHER RI
Citation: Ri. Fisher, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE VERSUS INTENSIVE CHEMOTHERAPY IN NON-HODGKINS-LYMPHOMA, Cancer chemotherapy and pharmacology, 40, 1997, pp. 42-46

Authors: HANADA S UTSUNOMIYA A SUZUKI S UOZUMI K MAKINO T ARIMA T
Citation: S. Hanada et al., TREATMENT FOR ADULT T-CELL LEUKEMIA, Cancer chemotherapy and pharmacology, 40, 1997, pp. 47-50

Authors: OGURA M KAGAMI Y SUZUKI R MIURA K UEHIRA K KUROKAWA T ITO T KINOSHITA T EMI N MORISHIMA Y KODERA Y UEDA R
Citation: M. Ogura et al., PHASE I II TRIAL OF CURE-ORIENTED HIGH-DOSE CHEMORADIOTHERAPY WITH TRANSPLANTATION OF CD34(+) PERIPHERAL-BLOOD STEM-CELLS PURIFIED BY THE IMMUNOMAGNETIC BEAD METHOD FOR REFRACTORY HEMATOLOGICAL MALIGNANCIES/, Cancer chemotherapy and pharmacology, 40, 1997, pp. 51-57
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>